文献速递血栓与止血

当代多中心队列中疑似肝素诱导的血小板减少症患者的结局

Outcomes of patients with suspected heparin-induced thrombocytopenia in a contemporary multicenter cohort.
PubMed 文献 · Blood Adv · 2025-01-01

这项前瞻性多中心队列研究纳入11个中心连续收治的1393例疑似肝素诱导的血小板减少症(HIT)患者,以洗涤血小板肝素诱导的血小板激活试验为参考标准诊断HIT。结果显示HIT确认者占8.5%,阿加曲班为主要治疗药物(70%),HIT患者中静脉血栓栓塞、动脉血栓栓塞、大出血和死亡率分别为23%、9%、12.6%和18%,不同抗凝药间无显著差异;阿加曲班、比伐卢定或直接口服抗凝药(DOACs)可显著降低动脉血栓栓塞风险。

要点

  • 疑似HIT患者中仅8.5%经洗涤血小板肝素诱导的血小板激活试验确认HIT。
  • HIT患者中静脉血栓栓塞23%、动脉血栓栓塞9%、大出血12.6%、死亡率18%。
  • 阿加曲班、比伐卢定或DOACs治疗显著降低动脉血栓栓塞风险。

核心结论

  • HIT以及仅疑似HIT仍是严重疾病,具有包括死亡在内的高不良结局风险。
  • 研究结果进一步支持DOACs、阿加曲班和比伐卢定在降低动脉血栓栓塞风险方面的有效性。

研究设计与样本

  • 前瞻性、多中心队列研究,纳入11个中心连续收治的疑似HIT患者。
  • 共纳入1393例患者(46%女性,中位年龄67岁),分为HIT确认组、HIT阴性但肝素/血小板因子4(PF4)抗体阳性组和HIT阴性且无抗体组。
  • 以洗涤血小板肝素诱导的血小板激活试验为参考标准诊断HIT。

主要发现

  • 1393例患者中HIT确认119例(8.5%)。
  • 多数患者住重症监护病房(37%)或接受过心脏手术(32%)。
  • 阿加曲班为主要治疗(70%),HIT患者中77%出现血小板恢复。
  • HIT患者中后续静脉血栓栓塞23%、动脉血栓栓塞9%、大出血12.6%、死亡率18%,不同抗凝药间无显著差异。
  • HIT阴性患者中有或无肝素/PF4抗体者结局无差异。

关键数值与推荐

  • HIT确认率8.5%(119/1393)。
  • HIT患者中静脉血栓栓塞23%、动脉血栓栓塞9%、大出血12.6%、死亡率18%。
  • 阿加曲班、比伐卢定或DOACs治疗显著降低动脉血栓栓塞风险。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Managing patients with suspected heparin-induced thrombocytopenia (HIT) poses significant clinical challenges. Limited evidence exists on how management decisions impact clinical outcomes, leading to treatment recommendations based on low-certainty evidence. This study aimed to evaluate the treatment strategies and clinical outcomes of patients with suspected HIT in a contemporary multicenter cohort. We conducted a prospective, multicenter cohort study including consecutive patients with suspected HIT from 11 centers. Patients were stratified into 3 groups: (1) HIT confirmed, (2) HIT-negative but heparin/platelet factor 4 (PF4) antibody-positive, and (3) HIT-negative without antibodies. Clinical and laboratory data were systematically collected. HIT was diagnosed using the washed-platelet heparin-induced platelet activation test as the reference standard. Among 1393 patients (46% female, median age 67 years), HIT was confirmed in 119 (8.5%). Most patients were in intensive care (37%), or had undergone cardiac surgery (32%). Argatroban was the predominant treatment (70%), and platelet recovery occurred in 77% of patients with HIT. Among patients with HIT, subsequent venous thromboembolism occurred in 23%, arterial thromboembolism in 9%, major bleeding in 12.6%, and mortality in 18%, with no significant differences between anticoagulants. Treatment with argatroban, bivalirudin, or direct oral anticoagulants (DOACs) significantly reduced arterial thromboembolism risk. Outcomes did not differ between patients who were HIT-negative with or without heparin/PF4 antibodies. HIT, as well as the mere suspicion of HIT, remains a serious condition with a high risk of adverse outcomes, including death. Our findings provide further evidence supporting the effectiveness of DOACs, argatroban, and bivalirudin in reducing arterial thromboembolism risk.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Nilius H, Sinitsa E, Studt JD, et al. Outcomes of patients with suspected heparin-induced thrombocytopenia in a contemporary multicenter cohort. Blood Adv. 2025. PMID: 40758946. doi:10.1182/bloodadvances.2025016639

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。